article
Expert view: High-throughput binding kinetic analysis – is it the new frontier in drug discovery?
Sometimes the difference between identifying a partial or super agonist is only the time point at which the binding reaction is measured.
List view / Grid view
Analytical techniques
article
Stem Cells In-Depth Focus 2018
In this issue: urine-derived stem cells offer an innovative platform for drug testing and disease modelling, a paradigm shift in translational stem cell research, and the role of biomaterials in stem cell-based regenerative medicine.
article
Could fingerprints play a role in drug trials of the future? A forensic scientist’s perspective
Although readers of Drug Target Review may be more focused upstream of clinical trials in the drug discovery pipeline, the efficacy of clinical trials should also be of interest. Millions of pounds invested in drug discovery in the laboratory could easily go to waste if the clinical trials stage is…
news
13th International Conference on Metabolomics and Systems Biology
Euro Metabolomics 2018 will be a platform to investigate on recent research and advancements that can be useful to the researchers.
news
New study discovers cancer-relevant protein shield
Researchers have uncovered a new protein shield that aids in repairing damaged DNA in cells and affects resistance to drugs used for breast cancer treatment...
news
Blood test may predict future risk of cardiovascular events
A study of 27,000 women finds that branched-chain amino acid levels in the bloodstream are as predictive of heart disease as LDL cholesterol, other risk factors...
article
How the study of lipidomics is benefiting from recent advances in mass spectrometry
There are no short-cuts in the complex field of lipidomics, explains Cristina Legido-Quigley, a Principal Investigator in Systems Medicine at Steno Diabetes Center Copenhagen in Denmark and at King’s College London.
article
Versatile applications of next-generation sequencing in pharmaceutics
Next-generation sequencing (NGS) technologies hold great promise for unravelling the mysteries of biological systems, with the advent of DNA sequencing methods having greatly accelerated biomedical research, gaining broad applicability in disease diagnosis and therapeutics in recent years...
article
A picture is worth a thousand endpoints: high-content imaging in drug discovery
Over the past few years several factors in the drug discovery industry have come together to drive an increased interest and subsequent surge in the use of high-content imaging. These include the high costs of attrition in the clinic due to lack of efficacy; increased hurdles and rising costs to…
article
Analysing recombinant proteins by mass spectrometry
The drug discovery landscape is changing: no longer limited to big pharma, it is now within reach of academics and small consortia alike. Regardless of the setting, drug discovery requirements are always the same: strong biological theory, good chemical starting material and high quality protein samples from which to determine…
article
Mass spectrometry and systems biology approaches in drug target discovery
Cells, organs and organisms are complex biological systems consisting of inter-related components that co-operatively work to maintain function and respond to change. Malfunction of any component can lead to pathologies and disease, leading to system-wide changes and subsequent adaptation. Hence, the ability to study and predict system behaviour will considerably…
article
Should LC-MS/MS proteomics guide targeted drug selection for cancer patients?
History has demonstrated that the use of companion in vitro diagnostic tests to select cancer patients positive for a drug target significantly improves response to targeted anti-cancer therapies...
article
Data automation in large-scale omics-based biomedical research
Medicine and life sciences research are being revolutionised by major technological developments that have taken place over the past decade. High-throughput sequencers can now generate high-quality nucleotide sequence data at a small fraction of the cost compared to only a few years back...
